bullish
Alteogen (196170 KS): Modified License Agreement For Major Platform Technology Is A Hard Catalyst
Tina has highlighted this Insight as a Top Pick
682 Views23 Feb 2024 04:58
SUMMARY
- Alteogen Inc (196170 KS) has modified the existing license agreement with Merck. Revised terms of the agreement grant Merck exclusive global right to ALT-B4 for a specific product group, pembrolizumab.
- Under the terms of the revised agreement, Alteogen will receive an upfront payment of $20M from Merck. Alteogen will also receive additional milestone payment of up to $432M.
- Approval of Alteogen’s first proprietary product, Tergase (expected in early 2024) will be the next major catalyst for the company.
Related Insights
More »- Alteogen: 2nd Largest Shareholder Raises Stake & Requests Switching Listing from KOSDAQ to KOSPI
- Alteogen (196170 KS): More ALT-B4 Licensing Deal to Follow; Fund Raise Wipes Off Uncertainty
- KRX New Deal Index Rebalance Preview: Potential Changes as Review Period Ends Today
- Alteogen (196170 KS): Transitioning Toward Becoming Commercial Stage Biotech Company
- Alteogen: Block Deal Sale of About 3% of Shares
Trending Collections
More »Trending Insights
More »- [Quiddity Index] Van Eck Gold Miners ETF (GDX) - Benchmark Change for Sep Rebal - $2.8bn One Way
- LQ45 Index Rebalance Preview (Jul 2025): Identifying Potential Index Changes
- SM Investments Placement: Large Deal to Digest
- [Japan M&A] Polaris MBO for DD Group (3073) - Too Light But Probably a Done Deal
- HK-Listed Apparel & Footwear Screener July 2025: August 1st Deadline Approaches
Top Unpaywalled Insights
More »Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Alteogen (196170 KS): More ALT-B4 Licensing Deal to Follow; Fund Raise Wipes Off Uncertainty05 Feb 2025
- Alteogen (196170 KS): Transitioning Toward Becoming Commercial Stage Biotech Company11 Jul 2024
- Alteogen: Block Deal Sale of About 3% of Shares27 Mar 2024
- Alteogen (196170 KS): Modified License Agreement For Major Platform Technology Is A Hard Catalyst23 Feb 2024
- Alteogen (196170 KS): First Proprietary Product Approval in Korea To Improve Revenue Visibility05 Jan 2024
- Alteogen (196170 KS): Milestone Payments and Pipeline Progress Strengthen Business Growth Prospect19 Jun 2023
- Alteogen (196170 KS): Distinct Platform Technology; Biosimilar Pipeline; Potential Value Unlocking10 Feb 2023
x